SCHEMBL1131365

SCHEMBL1131365

CCOC(n1ccnn1)[Si](C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5400575 0.79 CYP19A1 (0.37) CYP19A1
SCHEMBL2659458 0.75 CYP19A1 (0.33) CYP19A1
SCHEMBL8890451 0.74
SCHEMBL6616364 0.74 ALDH1A1 (0.34)
SCHEMBL29959382 0.68 THRB (0.31)
SCHEMBL7268446 0.68 CYP19A1 (0.38) CYP19A1
SCHEMBL12369613 0.67 CYP19A1 (0.41) CYP19A1
SCHEMBL6999923 0.67 CYP19A1 (0.38) CYP19A1
SCHEMBL20397431 0.66
SCHEMBL14214803 0.66

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2638021-A2 METALLOENZYME INHIBITOR COMPOUNDS Viamet Pharmaceuticals, Inc. (US) 2013-09-18 EP disclosed
WO-2012064943-A2 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2012-05-18 WO disclosed
EP-1379498-B1 SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE MERCK SHARP & DOHME (GB) 2011-02-16 EP disclosed
US-7598386-B2 Sulphones which modulate the action of gamma-secretase MERCK SHARP & DOHME LIMITED (GB) 2009-10-06 US disclosed
US-7595344-B2 Sulphones which modulate the action of gamma secretase MERCK SHARP & DOHME LIMITED (GB) 2009-09-29 US disclosed
US-20090131419-A1 Sulphones which modulate the action of gamma secretase MERCK SHARP & DOHME (UK) LIMITED (GB) 2009-05-21 US disclosed
US-20080045533-A1 Novel cyclohexyl sulphones CHURCHER IAN 2008-02-21 US disclosed
US-7304094-B2 Alzheimer's disease, modulate the processing of amyloid precursor protein by gamma-secretase MERCK SHARP + DOHME 2007-12-04 US disclosed
US-20070213329-A1 Sulphones which modulate the action of gammasecretase MERCK SHARP & DOHME (UK) LIMITED (GB) 2007-09-13 US disclosed
US-20060041020-A1 Novel cyclohexyl sulphones MERCK SHARP & DOHME (UK) LIMITED (GB) 2006-02-23 US disclosed
US-6984663-B2 Treatment or prevention of Alzheimer's disease MERCK SHARP & DOHME LIMITED (GB) 2006-01-10 US disclosed
US-20040116404-A1 Sulphones which modulate the action of gamma secretase MERCK SHARP & DOHME LTD. (GB) 2004-06-17 US disclosed
EP-1379498-A1 SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE MERCK SHARP & DOHME LTD. (GB) 2004-01-14 EP disclosed
US-20030114496-A1 Novel cyclohexyl sulphones MERCK SHARP & DOHME (UK) LIMITED (GB) 2003-06-19 US disclosed
WO-2002081435-A1 SULPHONES WHICH MODULATE THE ACTION OF GAMMA SECRETASE MERCK SHARP & DOHME LIMITED (GB) 2002-10-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131419-A1 Sulphones which modulate the action of gamma secretase BACE1, BACE2, PSEN1 CYP19A1 1506/4885
US-20080045533-A1 Novel cyclohexyl sulphones BACE1, APP, PSEN1 CYP19A1 1650/4885
US-20060041020-A1 Novel cyclohexyl sulphones BACE1, APP, PSEN1 CYP19A1 1650/4885
US-20070213329-A1 Sulphones which modulate the action of gammasecretase BACE1, PSEN1, BACE2 CYP19A1 510/4885
US-20030114496-A1 Novel cyclohexyl sulphones BACE1, APP, PSEN1 CYP19A1 1485/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.